ArticleACG case reports journal2025
Vedolizumab as a Second Line Biologic for Cronkhite Canada Syndrome and an Approach Toward Disease Monitoring.
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: A case of Cronkhite-Canada syndrome associated with sigmoid colon cancer and early esophageal cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 62-year-old woman was diagnosed with Cronkhite-Canada Syndrome, presenting with classic clinical symptoms and endoscopic findings. She initially responded to infliximab (IFX) with symptomatic improvement, normalized calprotectin, and minimal disease activity on endoscopy for 3 years. Despite IFX trough levels appropriate for inflammatory bowel disease goals and no IFX antibodies, she subsequently lost response and had recurrence of symptoms and disease activity. She started on a course of corticosteroids, discontinued IFX, and transitioned to vedolizumab with standard induction and maintenance dose every 8 weeks, achieving clinical remission and near complete endoscopic remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.